CEO to Highlight Role Consumer Demand, A.I. and State Directives Plays in Shaping Regional Energy Market in Downstate New York

RONKONKOMA, N.Y., Sept. 30, 2026 (GLOBE NEWSWIRE) — SUNation Energy Inc. (Nasdaq: SUNE) (“SUNation” or the “Company”), a leading provider of solar energy and backup power solutions to residential, commercial, and municipal customers, today announced that Scott Maskin, Founder and CEO, will speak at the upcoming HIA-LI Energy Conference, joining regional business and energy leaders for a discussion on the rapidly changing forces shaping Long Island’s energy market.

Maskin’s remarks will focus on what businesses and consumers should expect in the year ahead as growing electricity demand, emerging technologies and evolving New York State energy policies place new pressures on the electric grid while creating new opportunities for distributed energy resources.

Among the most significant changes facing the industry is the accelerating growth of electricity demand. Artificial intelligence, data centers, transportation electrification, building electrification and the broader expansion of the digital economy are creating new sources of load at the same time consumers and businesses are becoming increasingly focused on energy costs, reliability and cost controls.

In addition, recent changes to New York’s building and energy codes demonstrate how state policy is increasingly connecting new construction with renewable energy deployment. Under the 2025 Energy Conservation Construction Code of New York State, qualifying new commercial buildings and residential buildings over three stories are generally required to satisfy a renewable-energy requirement through on-site generation or qualifying alternatives.

“The energy conversation has changed dramatically,” Maskin said. “For years, much of the discussion was centered on how quickly we could transition to cleaner sources of electricity. Today, we also have to answer an equally important question, where is this electricity needed to power the next generation of our economy going to come from, and how does government respond?”

The HIA-LI Energy Conference brings together business leaders, policymakers, utilities and energy-industry professionals to examine issues affecting Long Island’s economy and energy future, and is scheduled for October 23rd, 2026. You can learn more about the event here: https://members.hia-li.org/event-calendar/Details/powering-a-sustainable-future-2026-energy-update-1612587

About SUNation Energy, Inc.

SUNation Energy, Inc. is focused on growing leading local and regional solar, storage, and energy services companies nationwide. Our vision is to power the energy transition through grass-roots growth of solar electricity paired with battery storage. Our portfolio of brands (SUNation, Hawaii Energy Connection, E-Gear) provide homeowners and businesses of all sizes with an end-to-end product offering spanning solar, battery storage, and grid services. SUNation Energy, Inc.’s largest markets include New York and Hawaii, and the company operates in two (2) states.

Forward Looking Statements 

Our prospects here at SUNation Energy Inc. are subject to uncertainties and risks. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. The Company intends that such forward-looking statements be subject to the safe harbor provided by the foregoing Sections. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this presentation. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “projects”, “should”, or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. We caution readers not to place undue reliance upon any such forward-looking statements. The Company does not undertake to publicly update or revise forward-looking statements, whether because of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in the Company’s filings with the SEC which can be found on the SEC’s website at www.sec.gov.

Contacts:
Scott Maskin
Chief Executive Officer
+1 (631) 350-9340
smaskin@sunation.com

SUNation Energy Investor Relations
IR@sunation.com

 

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Beacon Financial Corporation (NYSE: BBT) announced today that it will report third quarter 2026 earnings at the close of business on Wednesday, October 21, 2026. Management will host a conference call to review this information at 1:30 PM Eastern Time on Thursday, October 22, 2026.

  • To listen to the call via the webinar, please visit: https://events.q4inc.com/attendee/438851030
  • To listen to the call, interested parties may dial (833) 461-5787 (United States) or (585) 542-9983 (internationally) and ask for the Beacon Financial Corporation conference call (Conference ID: 438 851 030).
  • A recorded playback of the call will be available for one week following the call at (833) 309-1852 (United States & Canada) or (929) 828-5978 (internationally). The passcode for this playback is 438 851 030. The call will be available live or in a recorded version on the Company’s website at beaconfinancialcorporation.com.

ABOUT BEACON FINANCIAL CORPORATION

Beacon Financial Corporation (NYSE: BBT) is the holding company for Beacon Bank & Trust, commonly known as Beacon Bank, a full-service regional bank serving the Northeast. Headquartered in Boston, the Company has $22.3 billion in assets and more than 145 branches throughout New England and New York. Beacon Bank offers a full suite of tailored banking solutions including commercial, cash management, asset-based lending, retail, consumer and residential products and services. The Company also provides equipment financing through its Eastern Funding subsidiary, SBA lending through its 44 Business Capital division, and private wealth services through Beacon Bank and Clarendon Private.

Beacon Financial Corporation
Carl M. Carlson
617-425-5331
Chief Financial and Strategy Officer

Collaboration advances Q/C Technologies’ optical processing unit initiative for AI inference through nanophotonics research at Sandia’s Center for Integrated Nanotechnologies

SAN FRANCISCO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C Technologies” or “the Company”), a developer of next-generation optical computing solutions, today announced a collaboration with the Center for Integrated Nanotechnologies (CINT) at Sandia National Laboratories (“Sandia”) to advance its proprietary optical processing unit (OPU) initiative for artificial intelligence inference. The Company is pioneering next-generation optical computing solutions designed to harness the properties of light to perform complex computations naturally via interference.

Sandia is one of the nation’s leading multi-mission science and engineering laboratories, operated for the U.S. Department of Energy’s National Nuclear Security Administration. With approximately 17,000 employees and an annual budget of approximately $5 billion, Sandia has deep capabilities spanning microelectronics, photonics, advanced materials, high-performance computing and systems engineering.

The Company’s collaboration with Sandia’s CINT focuses on joint research on nanophotonic components and the physical building blocks required for scalable optical AI processing. The project aims to establish and verify a defensible roadmap for optical AI hardware beyond incremental GPU scaling by identifying and prioritizing optical operations and device technologies for Q/C’s OPU architecture and addressing key challenges including nonlinear operations, memory, precision, optical loss and integration with electronic systems.

“Access to CINT’s scientific expertise and advanced research capabilities in photonics and nanoscale technologies represents an important step as we develop our proprietary optical computing platform,” said Joshua Silverman, Executive Chairman of Q/C Technologies. “As AI infrastructure faces increasing constraints in power consumption, bandwidth and scalability, we believe optical computing has the potential to fundamentally change how computationally intensive AI workloads are processed. This collaboration will help us evaluate key architectural concepts as we continue building the foundation for our next-generation optical computing solution.”

“This collaboration provides an opportunity to accelerate our work toward a practical, scalable optical computing architecture,” said Yossef Ehrlichman, Ph.D., Chief Technology Officer at Q/C Technologies. “We believe this work with CINT will help us define the pathway from fundamental optical capabilities to an integrated OPU architecture.”

The new collaboration represents another milestone in Q/C Technologies’ OPU initiative. The Company recently established a 4,800-square-foot integrated photonics laboratory in San Francisco and continues to build its foundation of knowledge and engineering expertise in AI, photonics and computing to support development of its proprietary OPU architecture.

About Q/C Technologies, Inc.

Q/C Technologies believes the next leap in frontier computing is optical. The Company is pioneering next-generation optical computing solutions designed to harness the properties of light to perform complex computations naturally via interference. Overcoming key challenges posed by electronic GPUs, Q/C Technologies seeks to develop proprietary optical processing units with orders of magnitude faster clock speed and bandwidth and vastly improved energy efficiency relative to traditional computing architectures. qctechnologies.com

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the development, performance and scalability of its optical computing products and related technologies, unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact its liabilities due to adverse market conditions, the Company’s ability to successfully develop new technologies; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to patent and otherwise protect its technologies from competitors; the Company’s ability to retain and attract senior management, engineers and other key employees; and the Company’s ability to quickly and effectively respond to new technological developments. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
800-507-9010

LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its joint venture partner Austrianova, today announced the successful encapsulation of GMP-quality Klotho-producing cells in the joint venture’s signature technology, Cell-in-a-Box® capsules.

After the successful completion of comprehensive adventitious agent and viral testing of its GMP Master Cell Bank (MCB), from which its Working Cell Bank (WCB) was recently established, Avaí Bio and global biotech, Austrianova, have completed an important milestone in the development of the Company’s genetically modified α-Klotho-producing cell line. Initial studies have demonstrated that the encapsulated cells remain viable, produce, and secrete high levels of the Klotho protein from within the capsules into the surrounding culture media.

This is a key functional objective of the platform. These results indicate that the capsule membrane supports both long-term cell containment and effective release of the therapeutic protein.

The achievement represents a significant technical milestone for the joint venture’s Klotho cell therapy program, providing the first confirmation that Klotho-expressing cells manufactured and banked under Austrianova’s GMP process can be successfully incorporated into the Cell-in-a-Box® delivery platform while maintaining their biological function.

“Our latest results demonstrate that Klotho-producing cells from the Working Cell Bank can be successfully encapsulated and express (produce) and secrete substantial amounts of the Klotho protein following encapsulation,” said Chris Winter, Chief Executive Officer of Avaí Bio. “These findings validate a critical component of our development strategy by confirming that the therapeutic cells remain functional within the Cell-in-a-Box® capsules and can release the target protein into the surrounding environment.”

Walter H. Gunzburg, Chairman and Chief Scientific Officer of Austrianova, said, “With successful encapsulation and confirmation of Klotho secretion now achieved, the program will advance to capsule expansion and optimization studies. These activities will evaluate growth characteristics, long-term functionality, and production performance of encapsulated Klotho-producing cells under conditions designed to support future development milestones.”

This latest milestone reported by the joint venture, Klothonova, a Nevada-based company equally owned by Avaí Bio and Austrianova’s affiliate, SG Austria Pte. Ltd, place the company well on track to develop a sustainable, long term production and delivery of α-Klotho—often referred to as the “longevity protein,” a central regulatory protein that is well documented for its anti-aging and protective effects on organs—in patients using Cell-in-a-Box® encapsulated cell-based therapies.

About Avaí Bio, Inc.
Avaí Bio, Inc. is an emerging biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies.

About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies.

More information about Avaí Bio can be found at https://www.avaibio.com
More information about Austrianova can be found at https://austrianova.com

You can also follow us on social media at:

https://x.com/AvaiBio
https://Facebook.com/AvaiBio
https://YouTube.com/@AvaiBio
https://Facebook.com/Austrianova

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

CONTACT: Avaí Bio, Inc.
info@avaibio.com

Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones

Access it here

OCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing how Ampligen® (rintatolimod) could fit into the evolving treatment landscape for pancreatic cancer.

In the CEO Corner, Equels discusses recent advances in pancreatic cancer treatment and why AIM believes Ampligen’s distinct immune-modulating approach warrants continued investigation. Rather than directly targeting a cancer-driving pathway, Ampligen has the potential to induce a broad-spectrum therapeutic effect that amplifies a patient’s innate immune response, creating the potential for a complementary role alongside or following therapies that act through different mechanisms.

The segment also highlights observations from a Dutch Named Patient Program (“NPP”) in which patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment. In an exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio (“NLR”) below 4.5, median overall survival was 34.8 months, measured from the start of FOLFIRINOX. This encouraging observation supports further investigation of Ampligen following chemotherapy.

Advances with FOLFIRINOX and daraxonrasib highlight the evolving treatment landscape in pancreatic cancer. The following chart summarizes the median overall survival results from the selected patients from NPP program as well as data from the separate clinical trials of FOLFIRINOX in metastatic pancreatic cancer and a daraxonrasib clinical trial of RAS G12 mutation patients with previously treated metastatic pancreatic cancer.

However, differences in patient selection, disease stage, treatment setting, and the timing of survival measurement prevent direct comparisons between the NPP findings and survival results from trials of these therapies. These findings provide a rationale for randomized studies to determine whether adding Ampligen after chemotherapy improves outcomes. Further research is also needed to establish whether NLR can identify patients more likely to benefit specifically from Ampligen, rather than patients with a generally more favorable prognosis.

AIM ImmunoTech Inc.

“Pancreatic cancer continues to present an urgent need for better treatment strategies, even as important new therapies emerge,” said Equels. “Ampligen approaches the disease differently through its potential to activate the innate immune response. We believe the powerful overall survival signal seen in the Named Patient Program, together with the clinical and biomarker data being generated through DURIPANC, will provide a compelling rationale to continue evaluating Ampligen’s potential role in pancreatic cancer. Ultimately, our goal is to get drug approval, which will be based on overall survival, in all probability focused on patients with neutrophil-to-lymphocyte ratios below 4.5.”

AIM is continuing to investigate Ampligen through the ongoing Phase 2 DURIPANC study evaluating Ampligen in combination with AstraZeneca’s durvalumab in metastatic pancreatic cancer. The study’s primary endpoint is Clinical Benefit Rate at 24 weeks following initiation of combination therapy, with topline results anticipated in the first quarter of 2027. The study is also evaluating progression-free survival, overall survival and immune profiling, with overall survival analysis expected to begin in 2027.

AIM anticipates topline results from DURIPANC in the first quarter of 2027, followed by its analysis of overall survival – the gold standard for drug approval – commencing in Q3 2027. If supported by the clinical and biomarker data, the Company believes the study could help define the parameters of a potential follow-up pivotal Phase 3 program and provide positive clarity around where Ampligen fits within an evolving pancreatic cancer treatment landscape.

The latest CEO Corner segment is now available on the Company’s website here.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: Ampligen’s potential efficacy and applicability in the treatment of pancreatic cancer; the timing of commencement, enrollment, completion, and results of clinical trials; intellectual property expansion and regulatory progress; and timing for receiving government approvals, if at all. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of pancreatic cancer. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/32219329-21da-4057-bdc6-8fb8989db060

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

A new joint venture focused on the localisation of self-propelled howitzer production is to be established during 2026 and start production in 2027. Over a seven-year period, the project represents a business opportunity worth EUR 1.8 billion.

On the occasion of the international ADEX defence exhibition in Baku, CSG group announced its intention to establish its second joint venture in Azerbaijan. The new company, created with a local partner, will focus on the gradual localisation of self-propelled howitzer production and the related transfer of CSG technologies and production know-how to Azerbaijan.

According to the current schedule, the joint venture is to be established in December 2026, while the start of production is planned for 2027. According to the current medium-term plan, the project represents a business opportunity worth EUR 1.8 billion over the next seven years. With regard to the agreed confidentiality arrangements, CSG is not disclosing the specific types of self-propelled howitzers, the planned production volumes or the identity of the local partner.

The new project follows the long-term development of CSG’s industrial activities in Azerbaijan and the first joint venture, VEXA DS, LLC, whose establishment the group announced in April 2026. VEXA DS focuses on the repair, servicing and modernisation of armoured vehicles and other land military equipment in Azerbaijan. The programme of this joint venture includes hundreds of pieces of equipment with a total value in the hundreds of millions of euros and an expected duration of ten years or more.

Azerbaijan is one of the markets where CSG is systematically building a long-term industrial presence combining production, servicing, modernisation and technology transfer. The planned second joint venture further develops this strategy: instead of a model based only on the export of finished products, CSG will combine its own technologies and know-how with gradually developed local production capacities and a long-term industrial partnership.

“The signing of agreements leading to the establishment of our second joint venture in Azerbaijan confirms that we are building a long-term industrial presence here. After servicing and modernisation of land military equipment, we are now expanding our cooperation to include the localisation of production. The project, with business potential of EUR 1.8 billion over the next seven years, represents a significant long-term opportunity for CSG. At the same time, our model is not based only on the export of finished products, but on a combination of our own technologies, local production, know-how transfer and long-term industrial partnership,” said Jan Marinov, CEO of the CSG Defence Systems division.

The localisation of production will take place gradually in several phases. CSG will bring its technological and production know-how in the field of land artillery systems to the project and will participate in the gradual development of production capacities directly in Azerbaijan. This model 2 / 3

enables CSG to build a long-term industrial presence in strategic foreign markets and, at the same time, to provide partners with access to the technologies and capabilities needed for the development of their own defence industry. The planned joint venture is part of CSG’s broader strategy based on long-term industrial partnerships, technology transfer and the development of local production and servicing capacities in strategic foreign markets.

The ADEX trade fair also serves as an opportunity to showcase products from companies within the CSG group. Exhibitors in Baku include Tatra Export (representing the vehicle manufacturer Tatra Trucks), as well as Excalibur International, Excalibur Army, MSM Group, and AviaNera Technologies. Representatives from Tatra Export are presenting the full portfolio of Tatra vehicles to potential customers – specifically the Force and Tactic model series designed for armed forces. Excalibur International is showcasing the Tadeas 6×6 armored vehicle, built on a Tatra chassis, and the Viking multifunctional mobile combat system designed to destroy targets such as UAVs, aircraft, helicopters, guided missiles, bombs, and precision-guided munitions at low or extremely low altitudes, as well as land and naval targets. Also on display are the ReGuard compact mobile 3D radar for air defense systems capable of detecting and tracking drones with a small radar cross-section and the CM-70 Spear – an advanced, cost-effective C-UAS guided interceptor designed to destroy UAVs.

Excalibur Army is presenting the modern Morana 155mm gun-howitzer in Baku; this system utilizes a highly mobile Tatra chassis and complies with all NATO standards for artillery systems and ammunition. AviaNera Technologies is exhibiting the MTF4000 series engine, designed for modern defense platforms such as cruise missiles, target drones, and anti-ship missiles. In Baku, the MSM Group is showcasing 155mm and 122mm artillery ammunition, as well as various types of 120mm and 105mm tank ammunition – standards for modern NATO main battle tanks and artillery systems. Also on display are 122mm unguided rockets for Grad-type launchers, medium-caliber 30×165mm ammunition, and mortar rounds in 60mm, 81mm, and 120mm calibers.

Attachment

30 September 2026

LEI: 2138003QW2ZAYZODBU23

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY (THE “ISSUER”)
(a public company incorporated with limited liability in Ireland)

1) WISDOMTREE S&P 500 3X DAILY LEVERAGED (ISIN: IE00B7Y34M31)
2) WISDOMTREE NASDAQ 100 3X DAILY LEVERAGED (ISIN: IE00BLRPRL42)
3) WISDOMTREE MAGNIFICENT 7 3X DAILY LEVERAGED (ISIN: XS3091654114)
4) WISDOMTREE PHLX SEMICONDUCTOR 3X DAILY LEVERAGED (ISIN: XS3091657729)
(TOGETHER THE “FS AFFECTED SECURITIES”)
5) WISDOMTREE S&P 500 3X DAILY SHORT (ISIN: IE00B8K7KM88)
6) WISDOMTREE NASDAQ 100 3X DAILY SHORT (ISIN: IE00BLRPRJ20)
7) WISDOMTREE MAGNIFICENT 7 3X DAILY SHORT (ISIN: XS3091657307)
8) WISDOMTREE PHLX SEMICONDUCTOR 3X DAILY SHORT (ISIN: XS3091646797)
(THE “SBR AFFECTED SECURITIES”, TOGETHER WITH THE FS AFFECTED SECURITIES, THE “AFFECTED SECURITIES”)

NOTIFICATION OF CHANGE OF THE STOCK BORROW RATE AND FUNDING SPREAD OF THE AFFECTED SECURITIES

Terms not defined in this notice shall have the meaning ascribed to them in the Issuer’s Base Prospectus dated 22 April 2026.

BNP Paribas acts as Swap Provider for the Affected Securities.

As permitted under paragraph 2.2(iii) of Annex A of the Conditions of the Affected Securities, the Swap Provider has notified the Issuer of its intention to amend i) the Funding Spread in respect of the FS Affected Securities and ii) Stock Borrow rate in respect of the SBR Affected Securities (the “Rate Changes”).     

The Rate Changes are detailed at Annex 1 hereto.

The Trustee, the Manager and the Issuer have entered into omnibus amendment deed to amend the Supplemental Trust Deeds relating to the Affected Securities to effect the Rate Changes (the “Affected Securities Amendments”).  The effective date of the Affected Securities Amendments shall be 1 October 2026.

For further information, please contact: europesupport@wisdomtree.com

Annex 1

The Rate Changes

FS Affected Securities

  (A) Primary Ticker (B) Name of Impacted Security (C) ISIN (F) Current
Funding
Spread
(G) New
Funding Spread
1 3USL WisdomTree S&P 500 3x Daily Leveraged IE00B7Y34M31 1.2450% 1.0020%
2 QQQ3 WisdomTree NASDAQ 100 3x Daily Leveraged IE00BLRPRL42 1.2450% 1.0020%
3 3MG7 WisdomTree Magnificent 7 3x Daily Leveraged XS3091654114 1.2450% 1.0020%
4 3SEM WisdomTree PHLX Semiconductor 3x Daily Leveraged XS3091657729 1.2450% 1.0020%


SBR Affected Securities

  (A) Primary Ticker (B) Name of Impacted Security (C) ISIN (D) Current Stock Borrow Rate (E) New Stock Borrow Rate
1 3USS WisdomTree S&P 500 3x Daily Short IE00B8K7KM88 0.1150% 0.3580%
2 QQQS WisdomTree NASDAQ 100 3x Daily Short IE00BLRPRJ20 0.1150% 0.3580%
3 3M7S WisdomTree Magnificent 7 3x Daily Short XS3091657307 0.1150% 0.3580%
4 SC3S WisdomTree PHLX Semiconductor 3x Daily Short XS3091646797 0.1150% 0.3580%

 Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release

No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy

Biodistribution study showed no significant ERNA-101 signal in tumor-free animals or non-tumor tissues, supporting ERNA-101’s tumor-homing delivery strategy

Encouraging safety results build on previously reported complete tumor clearance and durable survival in ovarian cancer models, strengthening the nonclinical foundation for ERNA-101

Core IND-enabling safety studies complete; GMP manufacturing underway; Company remains on track for planned Q4 2026 IND submission

CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced highly encouraging results from three core Investigational New Drug (IND)-enabling safety studies of ERNA-101, its lead synthetic, allogeneic induced mesenchymal stromal cell (iMSC) therapy engineered to express an IL-7/IL-15 fusion cytokine.

Across repeat-dose GLP toxicology, tumorigenicity and biodistribution studies, ERNA-101 demonstrated a favorable nonclinical safety profile, with results addressing three critical questions as the Company prepares to advance the program toward first-in-human development:

  • Repeat-dose safety: No ERNA-101-related adverse findings were observed at any dose level tested in a 50-day GLP toxicology study in tumor-bearing mice with an intact immune system.
  • Tumorigenicity: No teratoma formation was observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing an important safety consideration for an iPSC-derived therapy.
  • Biodistribution: No significant ERNA-101 signal was detected in tumor-free animals or non-tumor tissues, supporting ERNA-101’s design to home to tumors without taking up residence elsewhere in the body.

Importantly, the results add a critical safety dimension to previously reported ERNA-101 efficacy data demonstrating complete tumor clearance and durable long-term survival in preclinical ovarian cancer models when combined with PD-1 blockade. Together, Ernexa believes the efficacy, safety and biodistribution findings provide an increasingly comprehensive nonclinical foundation for advancing ERNA-101 toward the clinic.

“We believe these results represent one of the most important milestones in Ernexa’s history because the ERNA-101 story is now coming together across efficacy, safety and tumor-targeted delivery,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “We have previously demonstrated compelling anti-tumor activity, including complete tumor clearance and durable survival in preclinical ovarian cancer models. Now, across three critical IND-enabling safety studies, we observed no ERNA-101-related adverse findings in our repeat-dose GLP study, no teratoma formation through the six-month tumorigenicity in-life phase and no significant ERNA-101 signal in tumor-free animals or non-tumor tissues.”

“From a scientific perspective, these findings provide important support for the fundamental design of ERNA-101,” said Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics. “Across repeat-dose toxicology, tumorigenicity and biodistribution, we are seeing encouraging results that strengthen the nonclinical foundation for advancing ERNA-101 toward the clinic.”

Luther continued, “In straightforward terms, these results support what we designed ERNA-101 to do: find the tumor, deliver powerful immune-enhancing cytokines where they are intended to work and limit unnecessary exposure elsewhere in the body. With our core safety studies complete, GMP manufacturing underway and our FDA Pre-IND meeting behind us, we remain on track for our planned IND submission in the fourth quarter of 2026. Our focus now is execution and moving ERNA-101 toward the milestone that matters most: treating our first patient.”

Repeat-Dose GLP Toxicology: No ERNA-101-Related Adverse Findings

In Ernexa’s pivotal 50-day GLP toxicology study, immunocompetent C57BL/6 mice with established ID8 ovarian tumors received ERNA-101 intraperitoneally once weekly for four doses at 0.33 × 10⁶, 1 × 10⁶ or 1 × 10⁷ cells per animal, compared with vehicle-treated controls.

The study was designed to evaluate ERNA-101 under conditions relevant to its planned clinical use, with tumor present, an intact immune system and repeat dosing.

Across all dose levels tested, there were:

  • No ERNA-101-related changes in clinical pathology;
  • No pathological evidence of treatment-related toxicity on microscopic evaluation by an independent board-certified veterinary pathologist; and
  • No treatment-related differences in the incidence or timing of unscheduled deaths, all of which were attributed to progression of the underlying tumor.

What the data mean: ERNA-101 is engineered to deliver an IL-7/IL-15 fusion cytokine directly into the tumor microenvironment. Cytokines can powerfully activate the immune system, but systemic exposure can also cause significant toxicity. Ernexa designed ERNA-101 to use the natural tumor-homing properties of mesenchymal stromal cells to concentrate cytokine activity within tumors while limiting systemic exposure. The absence of ERNA-101-related toxicity in the repeat-dose study, together with the absence of acute cytokine release in the single-dose assessment, provides important support for that design strategy.

“A cytokine-armed cell therapy needs to be evaluated where its biology is active, in the presence of tumor and an intact immune system,” said Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics. “That is what makes these results particularly encouraging. Across the repeat-dose study, we observed no ERNA-101-related adverse findings in clinical pathology or histopathology, and in the single-dose assessment, we observed no evidence of acute cytokine release. We believe the results support the fundamental concept behind ERNA-101: bring powerful immune activation to the tumor while limiting systemic exposure.”

Tumorigenicity: No Teratoma Formation Observed Through Six-Month In-Life Phase

Because ERNA-101 is derived from induced pluripotent stem cells, or iPSCs, tumorigenicity is an important component of its nonclinical safety assessment. Specifically, the studies evaluate whether the final differentiated ERNA-101 cell product could form unwanted tumors known as teratomas.

Ernexa has completed a three-month tumorigenicity study and the in-life phase of a six-month tumorigenicity study in immunocompromised NSG mice. No gross evidence of teratoma formation was observed in ERNA-101-treated groups.

Histopathologic assessment confirmed the absence of tumor formation in the three-month study. Histopathologic evaluation of the six-month study is ongoing and is expected to be completed prior to IND submission.

What the data mean: For an iPSC-derived cell therapy, demonstrating that the final cell product does not form teratomas is a fundamental safety consideration. The absence of teratoma formation through the six-month in-life phase provides an encouraging answer to this important question as Ernexa prepares its IND package.

Biodistribution: No Significant ERNA-101 Signal in Tumor-Free Animals or Non-Tumor Tissues

Ernexa also completed a five-week biodistribution and persistence study designed to answer another straightforward but critical question: Where do ERNA-101 cells go after they are administered?

ERNA-101 was evaluated in both tumor-bearing and tumor-free animals. Using highly sensitive digital droplet PCR (ddPCR) specific for ERNA-101, the Company found no significant ERNA-101 signal in non-tumor-bearing animals or non-tumor-containing tissues.

The findings are consistent with the intrinsic tumor-homing properties of mesenchymal stromal cells and prior studies in which ERNA-101 cells were detected within tumors.

What the data mean: Ernexa designed ERNA-101 to home to tumors, deliver its immune-enhancing payload and avoid taking up residence elsewhere in the body. The biodistribution results provide important support for that targeted-delivery strategy.

“Biodistribution goes directly to the heart of the ERNA-101 thesis,” Pierce said. “Put simply, we want the cells to go to the tumor, deliver their payload and not take up residence where they do not belong. Finding no significant ERNA-101 signal in tumor-free animals or non-tumor tissues is exactly the type of biodistribution profile we hoped to see and provides important support for the targeted delivery concept underlying our platform.”

Efficacy + Safety + Tumor-Homing: Building a More Complete ERNA-101 Profile

The newly reported safety results build on previously reported ERNA-101 preclinical efficacy findings.

In ovarian cancer models, ERNA-101 remodeled the tumor microenvironment from immunosuppressive to immune-activated and increased infiltration of CD4+ and CD8+ T cells. When combined with PD-1 blockade, ERNA-101 achieved a high rate of complete tumor clearance and durable long-term survival, findings that were validated in independent studies.

In simple terms, the preclinical development program has now begun to address three fundamental questions:

Can ERNA-101 mediate tumor clearance?
Preclinical efficacy studies demonstrated compelling anti-tumor activity, including complete tumor clearance and durable survival in ovarian cancer models.

Can ERNA-101 potentially do so with an acceptable safety profile?
The core IND-enabling studies showed no ERNA-101-related adverse findings in repeat-dose GLP toxicology and no observed teratoma formation through the six-month tumorigenicity in-life phase.

Does ERNA-101 go where it is designed to go?
Biodistribution studies showed no significant ERNA-101 signal in tumor-free animals or non-tumor tissues.

“We believe the significance is in the totality of the data,” Luther said. “Efficacy, safety and tumor-homing are not separate stories, they are interconnected parts of the same ERNA-101 thesis. The preclinical evidence generated to date is giving us encouraging answers across all three dimensions. That strengthens our conviction in the program as we prepare for the transition from preclinical development into the clinic.”

Accompanying chart

Advancing Toward a Planned Q4 2026 IND

Completion of the core IND-enabling safety studies represents another major step in Ernexa’s planned transition toward becoming a clinical-stage oncology company.

The Company has completed its FDA Pre-IND meeting, completed its core IND-enabling safety studies and is advancing clinical-grade GMP manufacturing of ERNA-101.

Ernexa remains on track to submit an IND for ERNA-101 in Q4 2026 for a first-in-human clinical study in platinum-resistant ovarian cancer. Subject to IND clearance, the Company intends to initiate the study and dose the first patient, with initial clinical data currently expected in Q4 2027.

“There is a point in the development of every potentially important new therapy when the question begins to change,” Luther concluded. “The question is no longer simply whether the science looks promising. It becomes whether you have built the foundation necessary to take that science into patients. With compelling preclinical efficacy, encouraging safety results, our core IND-enabling studies complete and manufacturing underway, we believe Ernexa is approaching that moment.”

Mr. Luther continued, “Our objective now is clear: execute the IND submission, advance ERNA-101 into the clinic and begin determining whether the promise we have observed in preclinical models can translate into meaningful benefit for patients. For women facing platinum-resistant ovarian cancer, better treatment options are urgently needed. That need gives purpose to every milestone we achieve and urgency to everything that comes next.”

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stromal cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/912c23d8-20bf-4df7-8861-e63dcd5874fd

PHOENIX, Sept. 30, 2026 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share).

The dividend will be payable on October 30, 2026, to holders of record at the close of business on October 16, 2026.

About Global Water Resources

Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 systems which provide water, wastewater, and recycled water service. The company’s service areas are located primarily in growth corridors around metropolitan Phoenix and Tucson. Global Water recycles over 1 billion gallons of water annually with 19.9 billion gallons recycled since 2004.

The company has been recognized for its highly effective implementation of Total Water Management (TWM). TWM is an integrated approach to managing the entire water cycle that involves owning and operating water, wastewater and recycled water utilities within the same geographic area in order to maximize the beneficial use of recycled water. It enables smart water management programs such as remote metering infrastructure and other advanced technologies, rate designs, and incentives that result in real conservation. TWM helps protect water supplies in water-scarce areas experiencing population growth.

Global Water has received numerous industry awards, including national recognition as a ‘Utility of the Future Today’ for its superior water reuse practices by a national consortium of water and conservation organizations led by the Water Environment Federation (WEF). The company also received Cityworks’ Excellence in Departmental Practice Award for demonstrating leadership and creativity in applying public asset management strategies to daily operations and long-term planning.

To learn more, visit www.gwresources.com.

Company Contact:
Michael Liebman
CFO and EVP
Tel (480) 999-5104
Email Contact

Investor Relations Contact:
Ron Both or Grant Stude
Encore Investor Relations
Tel (949) 432-7450
Email Contact

  • In a year-long functional magnetic resonance imaging (fMRI) study – a non-invasive method to measure brain activity during specific tasks – CagriSema changed how the brain reacted to tempting, high-calorie foods in areas linked to cravings, pleasure, and self-control in people living with overweight or obesity¹
  • In adults with type 2 diabetes, CagriSema reduced harmful fat around abdominal organs, including the liver and pancreas. Early findings also suggest that bone health was maintained despite substantial weight loss2,3
  • Together, these findings suggest CagriSema may address underlying factors of obesity and type 2 diabetes in the brain and multiple organs and tissues, including bones, not only weight and blood sugar levels1-3

Bagsværd, Denmark, 30 September 2026 – Novo Nordisk today announced new data on how CagriSema works inside both the brain and body, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026.

In a 52-week functional magnetic resonance imaging (fMRI) study, a brain scan technique that shows how the brain responds to cues, in adults with overweight or obesity, CagriSema modified brain responses to high-calorie food cues in regions linked to cravings, reward, sensory processing and behavioural control. Additionally, CagriSema substantially improved eating behaviour, reduced ‘food noise’, cravings, hunger, appetite, and food-related thoughts and improved craving control after both 22 and 52 weeks of treatment. In the study, also awarded a Best Abstract Award at EASD 2026, the improvements were also associated with a 22.4% reduction in body weight versus placebo at 52 weeks (estimated treatment difference at 52 weeks, p<0.0001).¹ Overall, the results suggest CagriSema may help address biological drivers that make sustained weight management difficult, including hunger, cravings and food preoccupation, not just calorie intake.

Separately, in a diabetes MRI sub-study, which evaluated whole body metabolic effects in the phase 3a REIMAGINE 1 trial in adults with early type 2 diabetes, CagriSema 2.4 mg/2.4 mg produced significant reductions in fat in the abdomen and around the liver and pancreas fat versus placebo, alongside a 14.3% body-weight reduction at week 40.² In addition, a post hoc analysis of bone markers of the phase 3 REIMAGINE 2 trial in adults with inadequately controlled type 2 diabetes showed signs of healthy balance in bone maintenance alongside a 14.2% body-weight reduction with CagriSema 2.4 mg/2.4 mg at week 68, providing what the study authors describe as “preliminary reassurance regarding bone changes with CagriSema in type 2 diabetes”.³

“For many people with overweight or obesity, we know that ‘food noise’ is an ongoing challenge to achieving health goals. Based on this brain scan (fMRI) data, we are encouraged by the potential of CagriSema to help reduce measurable ‘food noise’ coupled with a 22.4% reduction in body weight after 52 weeks,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. “At the same time, people living with overweight, obesity and type 2 diabetes are increasingly looking beyond the amount of weight lost to the quality of that weight loss. The data presented at EASD 2026 add to emerging evidence that the amylin component of CagriSema may influence disease biology across the brain and multiple organs beyond weight loss alone.”

Taken together, the three studies suggest investigational CagriSema may act on obesity and type 2 diabetes through coordinated effects on eating behaviour, fat levels in and around the organs, and bone remodelling – mechanisms that extend well beyond weight reduction itself.

“What is striking about this behavioural and brain fMRI data is that, after 52 weeks, across all measures of appetite and eating behaviour, people with overweight and obesity had substantially reduced food cravings and sustained changes in the brain response to viewing pictures of high-calorie foods,” said Professor Tony Goldstone, Clinical Professor in PsychoNeuroEndocrinology and Consultant Endocrinologist, Imperial College London. “This was coupled with reduced energy intake and body weight, showing the association between tackling ‘food noise’ and successful and sustained weight loss.”

CagriSema is Novo Nordisk’s next-generation investigational obesity and diabetes treatment. Novo Nordisk submitted an NDA for obesity to the US FDA and Health Canada in December 2025. In 2026, High-dose CagriSema 2.4 mg/7.2 mg, an efficacy and safety phase 3 trial, was initiated in adults with obesity.

Obesity and type 2 diabetes remain among the largest, most under-treated chronic disease burdens globally. According to the World Health Organization, more than one billion people worldwide are now living with obesity, and the International Diabetes Federation estimates that approximately 589 million adults are living with diabetes, the majority with type 2 diabetes.⁴,5

Beyond weight itself, obesity drives risk for cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD), chronic kidney disease and multiple cancers.6 Many people describe persistent thoughts about food – sometimes called ‘food noise’ – as a barrier to sustained weight loss, and current therapies have historically been evaluated primarily on scale weight rather than on the underlying drivers of eating behaviour or on where fat is stored in the body. Ectopic fat — fat accumulated in the liver, pancreas and around abdominal organs — is a key contributor to insulin resistance and progression of type 2 diabetes.7

The CagriSema studies presented at EASD 2026 are designed to address these gaps by measuring how the therapy affects the brain, behaviour, and body — not weight alone.

About CagriSema
Once-weekly subcutaneous CagriSema is being investigated by Novo as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin receptor agonist, cagrilintide, and a GLP-1 receptor agonist, semaglutide.

Novo filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema for weight management, demonstrating the company’s commitment to obesity innovation. A decision is expected in Q4 2026.

About the REDEFINE programme
REDEFINE is a phase 3 clinical development programme with once-weekly subcutaneous CagriSema in obesity. The global clinical trial programme includes two pivotal phase 3 trials that enrolled approximately 4,600 adults with overweight or obesity. The phase 3 trial programme includes:

  • REDEFINE 1 – a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes.
  • REDEFINE 2 – a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight.
  • REDEFINE 3 – an event-driven cardiovascular outcomes phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg versus placebo in 7,000 adults with established cardiovascular disease with or without type 2 diabetes.
  • REDEFINE 8 – a 104-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg versus placebo in 400 adults with obesity, including assessments on body composition. The trial includes a 52-week extension phase investigating maintenance of weight loss with CagriSema 2.4 mg/2.4 mg or a dose-tapering algorithm.
  • REDEFINE 9 – a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema 1.7 mg/1.7 mg and CagriSema 1.0 mg/1.0 mg versus placebo in 300 adults with overweight or obesity.
  • REDEFINE 11 – an 80-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg versus placebo in 600 adults with obesity. The trial includes an 80-week extension phase investigating the maintenance of weight loss.
  • High-dose CagriSema 2.4 mg/7.2 mg, an efficacy and safety phase 3 trial, was initiated in adults with obesity in 2026.

About the REIMAGINE programme
REIMAGINE is a phase 3 clinical development programme with once-weekly subcutaneous CagriSema in type 2 diabetes. The global clinical trial programme consists of several phase 3 trials. REIMAGINE 1 was a 40-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus placebo in 189 adults with type 2 diabetes inadequately controlled on diet and exercise. REIMAGINE 2 was a 68-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and placebo in 2,713 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor. REIMAGINE 3 was a 40-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus placebo in 274 adults with type 2 diabetes as an add-on to once-daily basal insulin with or without metformin.

Additionally, the REIMAGINE 4 and REIMAGINE 5 trials evaluated CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg, respectively, versus tirzepatide in adults with type 2 diabetes on standard of care.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Contacts for further information

Novo Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

_______________________
References

  1. Uhre VF, Alex M, Bak N, et al. Effects of CagriSema on appetite, eating behaviour and food cue reactivity using functional MRI in adults with overweight or obesity. Late-breaking abstract, EASD Annual Meeting 2026.
  2. Pratley RE, Adhya R, Casu A, et al. Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1. Late-breaking abstract, EASD Annual Meeting 2026. NCT06323174.
  3. Haluzík M, Fabricius TW, Gajria R, et al. Effect of CagriSema on bone biomarkers in participants with inadequately controlled type 2 diabetes: REIMAGINE 2. Late-breaking abstract, EASD Annual Meeting 2026. NCT06065540.
  4. World Health Organization. Obesity and overweight fact sheet. 8 December 2025.
  5. International Diabetes Federation. IDF Diabetes Atlas, 11th edition.
  6. Snel M, Jonker JT, Schoones J, et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol. 2012;2012:983814.
  7. Taylor R. Type 2 diabetes as a disease of ectopic fat? BMC Med. 2014;12:123.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.